Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
41.8M
-
Number of holders
-
156
-
Total 13F shares, excl. options
-
38.9M
-
Shares change
-
-789K
-
Total reported value, excl. options
-
$770M
-
Value change
-
-$20.6M
-
Put/Call ratio
-
1.03
-
Number of buys
-
73
-
Number of sells
-
-91
-
Price
-
$19.78
Significant Holders of Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) as of Q4 2024
200 filings reported holding KNSA - Kiniksa Pharmaceuticals International, plc - Common Stock as of Q4 2024.
Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) has 156 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.9M shares
of 41.8M outstanding shares and own 93.05% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (3.57M shares), BRAIDWELL LP (3.45M shares), VANGUARD GROUP INC (3.21M shares), BAKER BROS. ADVISORS LP (2.82M shares), Rubric Capital Management LP (2.62M shares), Fairmount Funds Management LLC (2.19M shares), HHLR ADVISORS, LTD. (1.58M shares), MORGAN STANLEY (1.49M shares), Pictet Asset Management Holding SA (1.13M shares), and Nuveen Asset Management, LLC (796K shares).
This table shows the top 156 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.